Last reviewed · How we verify
NDX-3315 and NDX-3324 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
NDX-3315 and NDX-3324 (NDX-3315 and NDX-3324) — NexEos Diagnostics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NDX-3315 and NDX-3324 TARGET | NDX-3315 and NDX-3324 | NexEos Diagnostics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NDX-3315 and NDX-3324 CI watch — RSS
- NDX-3315 and NDX-3324 CI watch — Atom
- NDX-3315 and NDX-3324 CI watch — JSON
- NDX-3315 and NDX-3324 alone — RSS
Cite this brief
Drug Landscape (2026). NDX-3315 and NDX-3324 — Competitive Intelligence Brief. https://druglandscape.com/ci/ndx-3315-and-ndx-3324. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab